Business
Interim Results 2006
Interim Results 2006.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n Hikma Pharmaceuticals Plc\n13 September 2006\n\n\n \n Hikma reports Interim Results for the six months to 30 June 2006\n\n• Revenue up 17.6% to $154.9 million\n\n• Profit attributable to shareholders up 19.9% to $30.1 million\n\n• On track for a record year of regulatory approvals\n\n• Positive outlook maintained for the full-year\n\nLONDON, 13 September 2006 - Hikma Pharmaceuticals PLC ('Hikma')(LSE: HIK) (DIFX:\nHIK) today announces its interim results for the six months to 20 June 2006.\nHikma is a multinational pharmaceutical group focused on developing,\nmanufacturing and marketing a broad range of generic and in-licensed\npharmaceutical products. Hikma operates in the United States, Europe and across\nthe MENA region.\n\nH1 2006 financial highlights\n\nRevenue up 17.6% to $154.9 million\n\nGross profit up 9.9% to $80.0 million\n\nR&D costs up 25.8% to $9.0 million\n\nOperating profit up 3.3% to $42.2 million\n\nProfit before tax up 9.5% to $42.4 million\n\nProfit attributable to shareholders up 19.9% to $30.1 million\n\nDiluted earnings per share* up 2.9% to 17.2 cents\n\nDividends per share* 3.0 cents\n\n\nOperational highlights\n\n• Strong revenue growth achieved in the Branded and Injectables businesses\n\n• On track for a record year of regulatory approvals, with 82 approvals in\n the first half, compared with 98 for the full year 2005\n\n• Capacity substantially increased across the Group to meet growing demand\n\n• Construction of the new cephalosporin plant in Portugal and R&D labs in\n Jordan nearing completion\n\n• In September, completed the acquisition of the 52.5% of JPI not\n previously owned by Hikma consolidating our position in the fast-growing\n Saudi and GCC markets\n\n\nCommenting on the results, Samih Darwazah, Chairman and Chief Executive of\nHikma, said:\n\n'Hikma has had a very successful start to 2006. Our Branded and Injectables\nbusinesses have performed particularly well and we have already secured almost\nas many regulatory approvals in the first half of 2006 as in the whole of 2005.\nWe are on track to continue to deliver further revenue growth in the second\nhalf, driven by improving conditions in the Algerian market, exceptional demand\nfor our Injectables products and new product launches in our Generic business in\nthe United States.'\n\n\nEnquiries:\n\nHikma Ph...